Team

Haihua Yu, Ph.D.

Co-founder & Chief Executive Officer

Dr. Yu has extensive experience in the development of visual integrated radiopharmaceuticals for diagnosis and treatment. In the 15 years of drug R&D prior to the co-founding of Bivision, he had successively served as a senior research scientist at the world-renowned GlaxoSmithKline, head of R&D and Director of BD at Huayi Technology, and Deputy General Manager at Huajing Molecular Imaging and Pharmaceutical Research Institute. He has built an integrated CDMO platform for targeted radiopharmaceuticals and a molecular imaging evaluation platform for preclinical drugs. His main areas of work are diagnostic and therapeutic drug development for neurodegenerative diseases, and the development of radiopharmaceuticals and TKI drugs.

Dr. Yu obtained his Ph.D. in Medicinal Chemistry from Fudan University. He has published more than 10 papers in internationally renowned journals, and holds more than 5 international patents.

Kevin Wang, Ph.D.

Co-founder & Chief Technology Officer

Dr. Wang is a highly innovative scientist and entrepreneur with over 20 years of biotech experience covering the full R&D process from drug design to market approvals. Prior to co-founding Bivision Pharma, he focused on the discovery and development in small molecule drug conjugates and targeted radionuclides at Endocyte, tackling a wide range of diseases including tumors, autoimmune diseases, and inflammation. Previously, he was with Eli Lilly hunting new drugs for CNS disorders.

Dr. Wang earned his Ph.D. from Queen’s University under the supervision of Professor Erwin Buncel, a fellow of the Royal Society of Canada. He trained as a postdoctoral fellow at the University of Wisconsin. He is the inventor of 15 granted U.S. patents and the author of 19 peer-reviewed papers.

Eric Wang, Ph.D.

Co-founder & Senior Vice President-Chemistry

Prior to co-founding Bivison, Dr. Wang had been involved in the R&D of novel small molecule drugs and radiopharmaceuticals at several pharmaceutical companies in the US for about 20 years. Back then, he was involved in, responsible for and led the development of orally administered macromolecules and first-in-class drugs in cancer, inflammation and central nervous system diseases, and has led the R&D of a series of radiopharmaceuticals for various biological targets at Progenics and Siemens Molecular Imaging and Biomarker Research.

Dr. Wang obtained his bachelor’s and master's degrees from Tianjin University, and Ph.D. from University of North Texas, and conducted his post-doctoral research in the laboratory of Dr. Mark M. Goodman’s, a prominent radiopharmaceutical expert, at Emory University School of Medicine. He has several NCEs entering clinical trials via IND application, with three NDAs(18F-Flortaucipir, Eligen B12 and Rybelsus) approved by the FDA for market launch. He holds 29 granted US drug invention patents, and has published 22 research papers in peer-reviewed journals.

Tony He, Ph.D.

Co-founder & Senior Vice President-Biology

Dr. He has extensive experience and unique insights in biopharmaceutical development and CMC. For more than a decade prior to co-founding Bivision, he had led and participated in the R&D of numerous antibody drugs and small molecule drugs at companies such as Roche, GlaxoSmithKline and Hepa Pharmaceuticals for cancer, CNS diseases and autoimmune disorders , many of which entered the late stage of clinical trials.

Dr. He obtained his Ph.D. from Fudan University and has published many research papers in Nature, PNAs, Nature Communications, etc..

Tony He, Ph.D.

Co-founder & Senior Vice President-Biology

Dr. He has extensive experience and unique insights in drug discovery and CMC. For more than ten years prior to Bivision, he had led or participated in numerous antibodies and small molecules development at  Roche, GlaxoSmithKline and Harbourbiomed for cancer, CNS and autoimmune  diseases, many of which entered late stage clinical trials.
Dr. He obtained his Ph.D. from Fudan University and has published his research work in Nature, PNAs, Nature Communications, etc..

Tony He, Ph.D.

Co-founder & Senior Vice President-Biology

Dr. He has extensive experience and unique insights in biopharmaceutical development and CMC. For more than a decade prior to co-founding Bivision, he had led and participated in the R&D of numerous antibody drugs and small molecule drugs at companies such as Roche, GlaxoSmithKline and Hepa Pharmaceuticals for cancer, CNS diseases and autoimmune disorders , many of which entered the late stage of clinical trials.

Dr. He obtained his Ph.D. from Fudan University and has published many research papers in Nature, PNAs, Nature Communications, etc..